

Pancreatic Cancer Committee meeting 5

Date: 15/09/2016

Location: RCOG, London

Minutes: Confirmed

Committee members present:	
John Primrose (Chair)	(Present for notes 1 – 7)
John Neoptolemos (Clinical Lead)	(Present for notes 1 – 7)
Fiona Campbell	(Present for notes 1 – 7)
Margred Capel	(Present for notes 1 – 7)
Richard Charnley	(Present for notes 1 – 7)
Pippa Corrie	(Present for notes 1 – 7)
Lesley Goodburn	(Present for notes 1 – 7)
Anna Jewell	(Present for notes 1 – 7)
Laura McGeeney	(Present for notes 1 – 7)
Somnath Mukherjee	(Present for notes 1 – 7)
Kofi Oppong	(Present for notes 1 – 7)
Derek O'Reilly	(Present for notes 1 – 7)
Philip Whelan	(Present for notes 1 – 7)

In attendance:		
Katie Perryman Ford	NICE Guideline Commissioning Manager	(Present for notes 1 – 7)
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 7)
James Hawkins	NGA Health Economist	(Present for notes 1 – 7)
Susan O'Connell	NGA Systematic Reviewer	(Present for notes 1 – 7)
Ferruccio Pelone	NGA Assistant Reviewer	(Present for notes 1 – 7)

Observers:	
None	

Apologies:	
Dawn Elliott	Committee member

Mark Callaway	Committee member
John Graham	NGA Clinical Adviser

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 5th meeting on Pancreatic Cancer.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: reviewing clinical evidence, drafting recommendations and agreeing the content of linking evidence to recommendations tables.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pancreatic cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

John Neoptolemos declared that he had signed a non-disclosure agreement with Redhill Biopharma Ltd to provide advice on an interventional non-medical treatment for pancreatic cancer. He will be paid a fee for his advice. This interest was categorised as personal financial specific meaning John Neoptolemos would have to withdraw from discussion of any topics which include an intervention made by Redhill Biopharma Ltd. It was noted that none of the interventions made by Redhill Biopharma Ltd are being covered by the guideline.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the other attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations

The Chair introduced James Hawkins, Health Economist, who gave a presentation

about the health economic analysis being conducted for the guideline. James then took questions from the group.

The Chair introduced Ferruccio Pelone, Assistant Systematic Reviewer, who gave a presentation on the clinical evidence for question 5e. Ferruccio then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

The Chair introduced Susan O'Connell, Systematic Reviewer, who gave a presentation on the clinical evidence for question 5a and 1. Susan then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.

5. Questions and discussion

The Committee discussed the clinical evidence presented for questions 5e, 5a and 1 and drafted recommendations and the section of the guideline linking evidence to recommendations.

The Committee discussed the proposed inclusion/exclusion criteria for the NMA for topic 5d and agree what they should be.

6. Any other business

No service user or carer concerns were raised.

Date of next meeting: 25&26/10/2016

Location of next meeting: RCOG, London